Advertisement

Breast Cancer Research and Treatment

, Volume 146, Issue 3, pp 567–572 | Cite as

Platinum-based chemotherapy in triple-negative advanced breast cancer

  • Cynthia Villarreal-Garza
  • Daniel Khalaf
  • Nathaniel Bouganim
  • Mark Clemons
  • Omar Peña-Curiel
  • Berenice Baez-Revueltas
  • Alexander Kiss
  • Farah Kassam
  • Katherine Enright
  • Sunil Verma
  • Kathleen Pritchard
  • Jeff Myers
  • Rebecca Dent
Clinical trial

Abstract

The purpose of this study was to evaluate the efficacy of platinum-based chemotherapy (PBC) versus conventional non-PBC regimens in a metastatic triple-negative breast cancer (TNBC) setting. We reviewed the electronic patient records of patients with confirmed metastatic TNBC at four major cancer centres in Canada. All patients were allocated into two groups based on type of chemotherapy received (PBC vs. non-PBC) and line of treatment (first-, second-, or third-line). The primary objective of this study was to evaluate the efficacy of PBC in metastatic TNBC in terms of median duration of overall survival (OS) from diagnosis of distant metastatic disease and compare it with the efficacy of conventional non-platinum-based chemotherapy in metastatic TNBC after controlling for known prognostic factors. A total of 153 metastatic TNBC patients were identified, 58 treated with PBC and 95 with non-PBC. The median time in first-line PBC versus non-PBC was not different between the two groups (2 vs. 2 months, p = 0.9), the median time on treatment in second and third-line therapy was longer for the PBC group compared to the conventional treated group (4 vs. 1 months, p = 0.004; 4 vs. 0.5 months, p = 0.004, respectively). Patients who received PBC had a longer OS compared to those managed conventionally (14.5 vs. 10 months, p = 0.041). This study evaluates the survival outcomes in a homogenous group of TNBC metastatic patients treated with or without PBC. Our results confirmed our hypothesis of a better OS among PBC-treated TNBC patients compared to conventionally managed TNBC patients. Currently ongoing Phase III trials assessing the benefit of PBC versus other chemotherapeutic regimens in advanced TNBC will help define the role of these agents for the management of this breast cancer subtype.

Keywords

Triple-negative breast cancer Platinum-based chemotherapy Metastatic triple-negative breast cancer 

Notes

Acknowledgments

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMedGoogle Scholar
  2. 2.
    Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657CrossRefPubMedGoogle Scholar
  3. 3.
    Kassam F, Enright K, Dent R et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9:29–33CrossRefPubMedGoogle Scholar
  4. 4.
    Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685CrossRefPubMedGoogle Scholar
  6. 6.
    Toft DJ, Cryns VL (2011) Minireview: basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol 25:199–211CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Turner N, Tutt A, Ashworth A (2004) Hallmarks of ‘BRCAness’ in sporadic cancers. Nat Rev Cancer 4:814–819CrossRefPubMedGoogle Scholar
  8. 8.
    Kim T, Lee H, Han S et al (2010) The comparison of the benefits obtained from platinum-containing chemotherapy between triple-negative and non-triple-negative metastatic breast cancer. J Clin Oncol 28:1071Google Scholar
  9. 9.
    Koshy N, Quispe D, Shi R et al (2010) Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19:246–248CrossRefPubMedGoogle Scholar
  10. 10.
    Sirohi B, Arnedos M, Popat S et al (2008) Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol 19:1847–1852CrossRefPubMedGoogle Scholar
  11. 11.
    Staudacher L, Cottu PH, Dieras V et al (2011) Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 22:848–856CrossRefPubMedGoogle Scholar
  12. 12.
    Uhm JE, Park YH, Yi SY et al (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124:1457–1462CrossRefPubMedGoogle Scholar
  13. 13.
    Bhattacharyya Gs BS, Agarwal V et al (2009) Single institute phaseII study of weekly cisplatinum and metronomic dosing of cyclophosphamide and methotrexate in second line metastatic breast cancer triple-negative. EJC suppl 7:18–19CrossRefGoogle Scholar
  14. 14.
    Fan Y, Xu BH, Yuan P et al (2012) P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC). Cancer Research 71:P5-19-04Google Scholar
  15. 15.
    Isakoff SJ, Goss PE, Mayer EL et al (2011) TBCRC009: a multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. J Clin Oncol 29:1025Google Scholar
  16. 16.
    Wang Z, Hu X, Chen L et al (2010) Efficacy of gemcitabine and cisplatin (GP) as first-line combination therapy in patients with triple-negative metastatic breast cancer: preliminary results report of a phase II trial. J Clin Oncol 28:1100Google Scholar
  17. 17.
    Verma S, Provencher L, Dent R (2011) Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 18:180–190PubMedCentralPubMedGoogle Scholar
  18. 18.
    O’shaughnessy J, Osborne C, Pippen JE et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214CrossRefPubMedGoogle Scholar
  19. 19.
    Baselga J, Stemmer S, Pego A et al (2011) Abstract PD01-01: cetuximab + cisplatin in estrogen receptor-negative, progesterone receptor-negative, her2-negative (triple-negative) metastatic breast cancer: results of the randomized phase ii bali-1 trial. Cancer Res 70:PD01-01Google Scholar
  20. 20.
    Cameron D, Brown J, Dent R et al (2012) Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer. Cancer Res 72:S6-5Google Scholar
  21. 21.
    Turner NC, Reis-Filho JS (2006) Basal-like breast cancer and the BRCA1 phenotype. Oncogene 25:5846–5853CrossRefPubMedGoogle Scholar
  22. 22.
    Ashworth A (2008) A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:3785–3790CrossRefPubMedGoogle Scholar
  23. 23.
    Decatris MP, Sundar S, O’byrne KJ (2004) Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev 30:53–81CrossRefPubMedGoogle Scholar
  24. 24.
    Khalaf D, Hilton JF, Clemons M et al (2014) Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression. Oncol Lett 7:866–870PubMedCentralPubMedGoogle Scholar
  25. 25.
    O’shaughnessy J, Schwartzberg LS, Danso MA et al (2011) A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 29:1007Google Scholar
  26. 26.
    Hurley J, Reis IM, Rodgers SE et al (2013) The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 138:783–794CrossRefPubMedGoogle Scholar
  27. 27.
    Von Minckwitz G, Schneeweiss A, Salat C et al (2013) A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto). J Clin Oncol 31:1004Google Scholar
  28. 28.
    Ding L, Ellis MJ, Li S et al (2010) Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464:999–1005CrossRefPubMedCentralPubMedGoogle Scholar
  29. 29.
    Peddi PF, Ellis MJ, Ma C (2012) Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer 2012:217185CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121:2750–2767CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Cynthia Villarreal-Garza
    • 1
    • 2
  • Daniel Khalaf
    • 3
  • Nathaniel Bouganim
    • 3
  • Mark Clemons
    • 3
  • Omar Peña-Curiel
    • 1
  • Berenice Baez-Revueltas
    • 4
  • Alexander Kiss
    • 2
  • Farah Kassam
    • 5
  • Katherine Enright
    • 5
  • Sunil Verma
    • 2
  • Kathleen Pritchard
    • 2
  • Jeff Myers
    • 6
  • Rebecca Dent
    • 2
    • 7
  1. 1.Instituto Nacional de CancerologíaCiudad de MéxicoMexico
  2. 2.Sunnybrook Odette Cancer CentreTorontoCanada
  3. 3.Division of Medical OncologyThe Ottawa Hospital Cancer Centre and University of OttawaOttawaCanada
  4. 4.Instituto Tecnológico Autónomo de MéxicoCiudad de MéxicoMexico
  5. 5.Princess Margaret HospitalTorontoCanada
  6. 6.Trillium Health Partners Peel Regional Cancer CentreMississaugaCanada
  7. 7.National Cancer Center SingaporeDuke-NUSSingaporeSingapore

Personalised recommendations